Evidence map›Paper›PMID 18612206›Full record

ArticleHuman heredity2008

Power of genetic association studies in the presence of linkage disequilibrium and allelic heterogeneity.

Sheila A Fisher, Cathryn M Lewis

Abstract read
In one paragraph

Article in Human heredity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.Movement disorders : official journal of the Movement Disorder Society · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sheila A FisherDivision of Genetics and Molecular Medicine, Institute of Psychiatry, King's College London, London, UK.
Cathryn M Lewis

Funding

Medical Research Council G0000934Wellcome Trust 068545/Z/02Wellcome Trust 072029Wellcome Trust 076024
6 · The paper itself

Abstract

objectivesThe calculation of the power and sample size required for association studies is essential, particularly for follow-up of genome-wide association studies, where much genotyping is required to replicate the original finding and identify the true disease susceptibility mutation.

methodsIn this paper, we derive equations for estimation of sample sizes for the transmission disequilibrium test (TDT) and for case-control studies, in the presence of allelic heterogeneity and indirect association - where the genotyped tagging SNP is in linkage disequilibrium (LD) with the true mutation. Using data from NOD2 and PTPN22, we show that the true sample sizes required to detect association may be incorrect when calculated under the assumption of a single mutation and complete LD with the genotyped marker.

resultsThe true sample sizes may be lower when allelic heterogeneity acts in a recessive model across mutations, or increased when mutations lie on different alleles of a common tagging SNP.

conclusionCalculating power and sample size under a range of realistic models of LD and allelic heterogeneity is essential to ensure that association studies have sufficient power to detect mutations.

Indexed as

Genetic HeterogeneityLinkage DisequilibriumModels, GeneticAllelesArthritis, RheumatoidCase-Control StudiesCrohn DiseaseGenetic LinkageGenetic Predisposition to DiseaseGenome, HumanHumansMutationNod2 Signaling Adaptor ProteinPolymorphism, Single NucleotideProtein Tyrosine Phosphatase, Non-Receptor Type 22Sample SizeNOD2 protein, humanNod2 Signaling Adaptor ProteinProtein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, human

Identifiers

PMID18612206
PMCPMC2787185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.